Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

ctDNA-guided de-escalation of adjuvant chemotherapy with dalpiciclib in HR-positive HER2-negative breast cancer

Phase 2 trial titled as ctDNA-guided de-escalation. Registry primary outcomes are the ctDNA clearance rate after neoadjuvant therapy and 3-year event-free survival. ClinicalTrials.gov lists the study as recruiting.

Peking University People's Hospital